News and Trends 6 Apr 2017 How is Biotech Transforming Pharma’s R&D Model? Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances and acquisitions play in this new model? For almost two centuries, medicinal products have brought continuous therapeutic progress. This path is marked by breakthrough innovations, which now allow us to treat diseases previously believed to be incurable. But to bring about […] April 6, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2017 Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares has announced the wrap-up of its preclinical programme for a new checkpoint inhibitor, AZD4635 that reverses adenosine-mediated T cell suppression and enhances anti-tumor immunity. The British company will now receive an €11M ($12M) milestone payment from AstraZeneca, who obtained exclusive global rights […] April 5, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Infographics 5 Apr 2017 Infographic: Europe’s Best Biotechs Mining the Microbiome We gathered the best of the best companies in Europe working on therapies from the microbiome — here are the names you should know! Justine Braguy is pursuing a PhD at the Heinrich Heine Universität in Düsseldorf and KAUST in Saudi Arabia after obtaining a Masters in Biotechnology at Ecole Supérieure de Biotechnologie de Strasbourg (ESBS). In her spare […] April 5, 2017 - 1 minutemin - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2017 Planning a Clinical Trial – Think Smart Design By using smart designs, sponsors can save time and money while optimizing the knowledge accrued during the development of their products. “Traditional” study designs and statistical methodology do not allow changing the main features of a study protocol once the study has been initiated. The use of interim analyses, and in particularly the development of […] April 5, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 4 Apr 2017 SynBioBeta Launches Venture Fund for Synthetic Biology Startups US-based venture capital fund Data Collective has announced that it is partnering with SynBioBeta to launch a new synthetic biology venture fund. Data Collective will join forces with SynBioBeta founder John Cumbers to launch the DCVC SynBioBeta fund, a pre-seed and seed VC fund to invest in synthetic biology startups. John Cumbers, an expert on […] April 4, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2017 Sample a More Efficient Sorbent to Streamline your mAb Purification Need an efficient way to purify your antibodies but struggle to find the best column? Pall Life Sciences is giving you the opportunity to try their solution for free. Enter your email below and receive your KANEKA Protein A sorbent sample! Pall Life Sciences is giving you a chance to try for free the new, […] April 4, 2017 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Apr 2017 Top Young Researchers Making Names for Themselves in Industry How long do you have to invest in academia before you can found a biotech company? Not as long as you might think, even for those going up the academic ladder. After profiling some of the biotech researchers that are most active in entrepreneurship and 10 impressive founders under 30, we have asked around for a combination of […] April 4, 2017 - 4 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2017 Massive €800M Acquisition of Belgian Biotech treating Menopause Astellas Pharma is acquiring Ogeda, getting hold of its promising Phase II candidate to treat menopause without hormonal therapy. After acquiring Ganymed Pharmaceuticals last October for a record €1.3B in German biotech, the Japanese Astellas Pharma is making a second massive acquisition in Europe. Its new addition is Ogeda, a Belgian biotech targeting GPCRs to treat gynecological […] April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 3 Apr 2017 First Treatment for Severe Premenstrual Syndrome Clears Phase II Swedish Asarina Pharma has announced positive results of a Phase IIa study for the treatment of Premenstrual Dysphoric Disorder (PMDD). With only a single product candidate in its pipeline, Asarina Pharma is focusing on the development of the first potential therapy for the treatment of PMDD, a severe and disabling form of premenstrual syndrome that affects about 5% of […] April 3, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2017 New Results Show GM Mosquitoes Keep Dengue and Zika at Bay in Brazil In its second year, Oxitec has reduced the mosquito population in a Brazilian neighborhood by 81%, demonstrating the long-term potential of GM insects. Oxitec is a spin-out from the University of Oxford that fights infectious disease with genetically-engineered mosquitoes that produce inviable offspring. The company has already made field trials in the Cayman Islands, Panama, Brazil, […] April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2017 UPDATE: First Woman CEO of a Global Drug Maker starts at GSK today GSK has punched a hole in the glass ceiling with its appointment of a new female CEO, Emma Walmsley. It’s up to her to reinvigorate the company. Emma Walmsley may be the most powerful woman in corporate Britain. The Oxford grad and L’Oreal veteran has just been crowned CEO of the pharma giant GSK: a marketing […] April 3, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 3 Apr 2017 Meet the Co-Founder who says DNA is the Next Silicon DNA Script opens the door to a whole new age of manufacturing synthetic DNA. Thomas Ybert, was only 30 when he co-founded the company – here’s his story! Based in Paris, DNA Script produces synthetic DNA using a proprietary template-free enzymatic technology. Most of the manufactured DNA is currently synthesized by chemical means, but this startup […] April 3, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email